Cyclosporine consensus conference: with emphasis on the treatment of psoriasis (Q77303806)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

review article

1 reference

title

Cyclosporine consensus conference: with emphasis on the treatment of psoriasis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference

1

M Lebwohl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

author name string

C Ellis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

A Gottlieb

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

J Koo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

G Krueger

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

K Linden

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

J Shupack

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

G Weinstein

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

language of work or name

English

0 references

publication date

1 September 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

Journal of the American Academy of Dermatology

4 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

page(s)

464-475

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

Cyclosporine as maintenance therapy in patients with severe psoriasis

4 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Individualized short-course cyclosporin therapy in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Low-dose cyclosporine A improves severe disabling psoriasis in Latin America. Latin American Multicenter Study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Cyclosporine in severe childhood atopic dermatitis: a multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Recalcitrant pyoderma gangrenosum responsive to cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Clearing of Pyoderma gangrenosum by intralesional cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Severe lichen planus clears with very low-dose cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Cyclosporin A mouthwash in the treatment of oral lichen planus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Cyclosporine in the treatment of generalized granuloma annulare

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Steroid-resistant bullous pemphigoid treated with cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Intractable epidermolysis bullosa acquisita: efficacy of cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Benign familial chronic pemphigus (Hailey-Hailey disease) responds to cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Long-term treatment of systemic lupus erythematosus with cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Scleroderma renal crisis as a possible complication of cyclosporin A withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Oral cyclosporine for severe chronic idiopathic urticaria and angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Actinic reticuloid: response to cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Purpura pigmentosa chronica successfully treated with oral cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Cyclosporine therapy for bullous erythema multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Annular elastolytic giant cell granuloma: response to cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Pityriasis rubra pilaris and cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Prevention of blisters in dystrophic recessive epidermolysis bullosa with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Darier-White syndrome and cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Failure of reticular erythematous mucinosis to respond to cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Cyclosporine in lamellar ichthyosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

National Transplantation Pregnancy Registry: report on outcomes in cyclosporine-treated female kidney transplant recipients with an interval from transplant to pregnancy of greater than five years

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

A prospective study of renal structure and function in psoriasis patients treated with cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Morphologic renal changes during cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Long-term safety of cyclosporine in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: Results of a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. An open-label extension study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Triple drug treatment with cyclosporine, leflunomide and mycophenolate mofetil prevents rejection of pig islets transplanted into rats and primates

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Combination leflunomide and cyclosporine prevents rejection of functional whole limb allografts in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

6-Thioguanine treatment of psoriasis: experience in 81 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

An approach to the treatment of moderate to severe psoriasis with rotational therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

Response of PUVA-induced keratoses to etretinate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970325-1

7 January 2021

10.1016/S0190-9622(98)70325-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9738783%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference